title: Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.
abstract: The present study examined the associations between a major adipokine, adiponectin, and adiposity indices as well as metabolic risk variables in a sample of 190 untreated asymptomatic men. Anthropometric measurements and a complete fasting plasma lipoprotein and lipid profile were obtained, and subjects underwent an oral glucose tolerance test. Fasting plasma adiponectin concentrations were determined by an ELISA. Although all adiposity and adipose tissue (AT) distribution indices were negatively correlated with plasma adiponectin levels (-0.14 </= r </= -0.32; P < 0.04), multiple regression analyses revealed that visceral AT accumulation was the only independent predictor of adiponectin levels, with 10% of its variance explained by visceral AT (P < 0.0001). Comparison of obese men with similar body mass index values (>/=30 kg/m(2)) but who markedly differed in their level of visceral AT (< vs. >/=130 cm(2); n = 15) revealed significant differences in adiponectin levels (7.0 +/- 3.0 vs. 11.1 +/- 4.9 microg/ml; P < 0.02 for men with high vs. low visceral AT, respectively). Finally, when men were stratified into tertiles of visceral AT and further classified on the basis of the 50th percentile of adiponectin levels (</= vs. >8.8 microg/ml), a 3 x 2 ANOVA revealed an independent contribution of adiponectin on the variation of high-density lipoprotein cholesterol levels (P < 0.002) and of the glucose area (P < 0.02). These results support the notion that adiponectin concentration is influenced to a greater extent by visceral than sc obesity. Furthermore, adiponectin predicts glucose tolerance and plasma high-density lipoprotein cholesterol levels in a manner that is partly independent from the contribution of visceral adiposity.
authors.affiliation: FAHA, Québec Heart Institute, Laval Hospital Research Center, 2725, chemin Ste-Foy, Pavilion Marguerite-D'Youville, 4th Floor, Ste-Foy, Québec, Canada G1V 4G5.
authors.forename: Mélanie
authors.initials: M
authors.lastname: Côté
authors.forename: Pascale
authors.initials: P
authors.lastname: Mauriège
authors.forename: Jean
authors.initials: J
authors.lastname: Bergeron
authors.forename: Natalie
authors.initials: N
authors.lastname: Alméras
authors.forename: Angelo
authors.initials: A
authors.lastname: Tremblay
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lemieux
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Després
mesh_terms: D052242:Adiponectin; D000273:Adipose Tissue / Q000000981:diagnostic imaging / Q000378:metabolism*; D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D005951:Glucose Tolerance Test; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000000981:diagnostic imaging / Q000453:epidemiology; D011237:Predictive Value of Tests; D012307:Risk Factors; D040521:Subcutaneous Tissue / Q000000981:diagnostic imaging / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D014781:Viscera
chemical_list: D052242:Adiponectin; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D036341:Intercellular Signaling Peptides and Proteins; D008074:Lipoproteins